Background
Acute myeloid leukemia (AML) is the most common acute leukemia worldwide and has high mortality rates, the overall median survival for patients with AML is 6.5 months due to limited treatment choices [
1,
2]. The current treatment options for patients with AML are bone marrow transplants, radiofrequency ablation and chemotherapy [
3]. Bone marrow transplants are only curative for a small percentage of matching patients [
4]. Meanwhile, the efficacy or response rate of radiofrequency ablation in advanced AML is pretty low [
5]. Chemotherapy, the only or necessary choice for most AML patients, is often limited by toxicities [
6]. Therefore, it is critical to discover effective drug treatments for AML patients.
Topotecan [10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin] (TPT), a semisynthetic topoisomerase 1 inhibitor derived from camptothecin (CPT), is active in patients with different types of solid tumors [
7‐
10]. TPT forms a covalent complex between Topoisomerase 1 and DNA, also called the cleavage complex, resulting in DNA damage during cell replication and transcription, ultimately leading to apoptosis [
11,
12]. This mechanism is being investigated for salvage and front-line therapy in AML patients combined with other medicines, such as etoposide, cytarabine, and cyclophosphamide [
13‐
17]. Unfortunately, clinical studies have shown that the activity of these therapies in AML is also limited due to their dose-dependent toxicity. Therefore, discovering potential drugs synergistic to the anticancer activity of TPT that do not enhance its toxicity is critical.
All-trans retinoic acid (ATRA) is a derivative of vitamin A that has good efficacy and has shown less side effects in APL during clinical observations [
18]. Experimental studies showed that ATRA treatment in AML affects leukemic cell morphology, regulation of cell cycle progression and apoptosis by activating nuclear receptors, including retinoic acid receptors (RAR types α, β, γ) and retinoid X receptors (RXR types α, β, γ) [
19]. Therefore, ATRA is the most promising agent to enhance the antitumor activity of TPT in AML.
In this study, we identified that the combination of TPT with ATRA have synergistic effects to AML in vitro and in vivo. Our study provides molecular insights for apoptosis involving TPT and ATRA by demonstrating that ATRA helps TPT cause serious DNA damage leading the AML cells HL60 to apoptosis, and RARα is involved in this process. Our results indicate that the TPT-ATRA combination may be a promising alternative chemotherapeutic strategy for AML.
Methods
Reagents
ATRA (cat # R2625) was obtained from Sigma (St Louis, MO, USA) and stored in ethanol at −40 °C. TPT, with more than 99 % purity, is synthesized by professor Wei Lu (East China Normal University) and dissolved in dimethylsulfoxide (DMSO) as stock solution at 10 mM. The stock solution was kept frozen in aliquot at −40 °C and thawed immediately prior to each experiment.
Cell line and cell culture
HL60, NB4 and U937, the human acute myelocytic leukemia cell lines, were obtained from ATCC, and they were maintained in complete media (RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) plus penicillin (100 units/ml) and streptomycin (100 ug/ml)) at 37 °C in 5 % CO2.
Cell Proliferation assay in vitro
The cytotoxic activity was detected by MTT assay. After Cells were cultured in 96-well plates at 4 × 103 cells/well, and allowed to proliferate to confluence in 5 % CO2 incubator at 37 °C overnight; exposed to different concentrations of TPT, ATRA or TPT combined with ATRA for 48 h. Cells were then incubated with MTT 5 mg/ml (Sigma, USA) for 4 h. A quantity of 100 ml of DMSO (dimethyl sulfoxide) was added to each well after removing the supernatant. Cell viability was obtained by measuring the absorbance on a Multiskan Spectrum (Thermo Electron Corporation, Marietta, Ohio) at 570 nm.
The growth inhibition was calculated according to the following formula: the Growth Inhibition Ratio (IR%) = [(the absorbance of blank control group – the absorbance of experimental group)/the absorbance of blank control group] × 100 %.
PI staining for flow cytometry
The sub-G1 analysis after PI staining was employed to assess the apoptosis. HL60 cells (105/ml) were seeded into 6-well plates and exposed to either or both of TPT and ATRA for 48 h. Cells were then harvested and washed with ice-cold PBS, fixed with precooled 75 % ethanol at −20 °C overnight. Cells were washed, and resuspended in 500 μl of PBS containing 100 μg/ml RNase (Amersco, Solon, OH, USA), then incubated at 37 °C for 30 min. After incubation, the cells were stained with 200 μg/ml propidium iodide (PI, Sigma, St Louis, MO, USA) in the dark at room temperature for 30 min. For each sample, at least 2 × 104 cells should be analyzed using an FACS-Calibur cytometer (BD Biosciences, Sanjose, CA), and the data were analyzed using cellquest software (BD biosciences).
JC-1 stain for mitochondrial membrane potential (△Ψm)
HL60 cells were inoculated into 6-well plates (150,000/well) for 24 h growth. After stabilisation for 24 h HL60 were treated with TPT, ATRA or both for 24 h and then harvested. Wash twice with PBS and suspend in 500 μl PBS with 2.5 μl JC-1 (20 μg/ml). Keep the samples in 37 °C, 5 % CO2, for 30 min. Then analyze immediatly with the flow cytometer, typically equipped with a 488 nm argon laser. JC-1 is a cationic dye that exhibits potential-dependent accumulation in mitochondria, indicated by a fluorescence emission shift from green (525 ± 10 nm) to red (610 ± 10 nm). Samples (1 × 104 cells/sample) were analyzed by FACS Calibur (Becton Dickinson, CA, USA).
Immunofluorescence
For morphological studies, exponentially growing cells were cultured in 3 × 105/well in 6-well plates and treated with TPT, ATRA or both for 48 h. The cells were washed with PBS, fixed with 0.1 % Triton X-100 for 15 min at room temperature, stained with 4’,6-dianidino-2-phenylindole dihydrochloride (DAPI, 2.0 μg/ml, Sigma) for another 15 min. Morphological changes of cell nucleus were examined in a fluorescence microscope, and they were photographed using a digital color camera DFC 300 FX (Leica, Wetzlar, Germany).
Western blot analysis
The protein samples were prepared as described previously. Briefly, proteins of HL60 cells were extracted in lysis buffer (150.0 mM NaCl, 50 mM Tris–HCl, 1 mM EDTA, 0.1 % SDS, 0.5 % dexoycholic acid, 0.02 % sodium azide, 1 % NP-40, 2.0 μg/ml aprotinin, 1 mM phenylmethylsulfonylfluoride). The lysates were centrifuged at 104 × g for 15 min at 4 °C. Equivalent amounts of proteins were analyzed by 8 %-15 % SDS-PAGE and electroblotted onto PVDF membranes (Millipore Corporation, Billerica, Massachusetts), and probed with primary antibodies. Appropriate antibodies to anti-caspase-3, anti-poly-ADP-ribose polymerase (PARP), anti-Bax, anti-chk1, anti-chk2 and anti-β-actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Bcl-2, anti-p-chk1, anti-p-chk2, and anti-γ-H2AX from Cell Signaling Technology (Beverly, MA, USA); and anti-Cytochrome C from Cell Signaling Technology (Boston, MA, USA) were used. The proteins were visualized with peroxidase-coupled secondary antibodies (Southern Biotech, Birmingham, UK), and using the enhanced chemiluminescence detection system (Biological Industries, Beit Haemek, Israel) for detection.
Alkaline comet assay
The alkaline comet assay, also called alkaline single-cell gel electrophoresis assay, was done according to the procedure of Huang et al. [
20]. with minor modification. Briefly, drug-treated HL60 cells (10
5/ml) were pelleted and resuspended in ice-cold PBS. A 50 μl sample of resuspended cells was the mixed with an equal volume of prewarmed 1 % low-melting point agarose. The cell-agarose mixture was placed on a slide precoated with 0.5 % agarose and spread gently with a coverslip. After 10 min at 4 °C, immersed the slides in precooled lysis buffer [2.5 M NaCl, 100 mM Na
2EDTA, and 10 mM Tris–HCl (pH 10)] for 90 min in the dark. After soaking with electrophoresis buffer (0.3 M NaOH and 1 mM EDTA) for 20 min, the slides were subjected to electrophoresis for 15 min. The cells were stained with DAPI at last, and individual cells were observed in a fluorescence microscope, and photographed by DFC 300 FX (Leica, Wetzlar, Germany).
Retroviral infection
To prepare the retroviruses, 293FT cells were plated at 6–8 × 105 cells per well in 6-well plates coated with 20 μg ml−1 of poly-ornithine. Twenty-four hours after plating, the cells were transfected with RARα shRNA plasmid, along with pUMVC and pCMV-VSV-G plasmids at the ratio of 2.125 μg of plasmid DNA to 5 μl of Lipofectamine 2000 in 500 μl Opti-MEM (both from Invitrogen). The ratio of shRNA:Pumvc: pCMV-VSV-G was 8:8:1. Twenty-four hours after transfection, the DMEM media was replaced with fibroblast (MEME) media. The next day the culture media containing the retroviruses was harvested and mixed 1:1 with 0.6 μg ml−1 polybrene (Sigma-Aldrich). The cell debris in the mixtures was removed using 0.45 μm low-protein-binding filters (Nalgene). The HL60 cells were plated at 2.5 × 105 cells per well in 6-well plates one day before infection with the retroviruses. The retrovirus solution was mixed with the cells for 6 h, then certain amount of fresh 1640 media was added for reducing the toxcity of polybrene. After infection of 24 h, cells were immediately transferred to complete RPMI-1640 supplemented with 10 % fetal bovine serum and cultured at 37 °C until analysis.
Lentivirus transduction
With Lipofectamine 2000, vesicular stomatitis virus-pseudo-typed vectors were produced by transient cotransfection of 293FT cells with 10 μg of the expression construct (pccl, or pccl-RARa), 10 μg of the pR△8.9 packaging plasmid, and 2 μg of the pMD.G envelope plasmid. Sodium pyruvate (Invitrogen) induction was performed according to the manufacturer’s instructions. After 72 h, the viral supernatants were harvested, centrifuged (800 g, 15 min), and filtered. After determination of the titer of the vector supernatants, HL60 cells were transduced with the indicated lentivirus particles (multiplicity of infection of 1 : 1) in the presence of 8 μgmL−1 polybrene. A second cycle of transduction was performed 24 h later with new viral supernatants in the presence of fresh polybrene. After 24 h, the cells were washed and cultured in fresh medium.
Animals and antitumor activity in vivo
Male immune-deficient nude mice at 4 weeks of age (National Rodent Laboratory Animal Resource, Shanghai Branch, China) were maintained in pathogen-free conditions with irradiated chow. Animals were unilaterally, subcutaneously (s.c.) injected with 5 × 10
6 HL60 cells/tumor in 0.1 ml Matrigel (Collaborative Biomedical Products, Bedford, MA). When HL60 cells formed palpable tumors, mice were divided randomly into 4 groups receiving control (n = 3), TPT alone (n = 3), ATRA alone (n = 3) or combination of both TPT and ATRA (n = 3). ATRA (5 mg/kg) was dissolved in corn oil and given to mice by gavage and TPT (2 mg/kg) was given to mice by intraperitoneal injection every two days of the experimental period. Control group received vehicle (0.5 % methylcellulose, 0.2 % Tween 80 and 99.3 % DDW, i.g. administration) everyday and 0.9 % saline solution by intraperitoneal injection every two days of the experimental period. Body weight and tumors were measured every two days. Tumor sizes were calculated by the formula: (length × width × width)/2, and the length, width and height is in millimeters. At the end of the experiment, animals were sacrificed by CO
2 asphyxiation and tumor weights were measured after their careful resection. Tumor tissue was collected for analysis. The individual relative tumor volume (RTV) was calculated according to the following formula: RTV = V
N/V
0, where V
N is the tumor volume on day n and V
0 is the tumor volume on day of initial treatment. Therapeutic effects of treatment were expressed in terms of T/C% using the calculation formula T/C (%) = mean RTV of the treated group/mean RTV of the control group × 100 % [
21]. All procedures were in accordance with the ethical standards of, and the protocols were approved by, the Animal Ethical and Welfare Committee (AEWC), Center for Drug Safety Evaluation and Research, Zhejiang University.
TUNEL assay
To evaluate the apoptotic response in tumor tissue, we applied terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick-end labeling (TUNEL) technique, to formalin-fixed tumor samples in paraffin blocks, using the one-step TUNEL apoptosis assay kit produced by Beyotime Institute of Biotechnology in China. The sections (4–5 μm) mounted on glass slides were deparaffinized, rehydrated thoursough graded alcohols to water, treated with 20 μg/ml proteinase K (37 °C, 20 min) and then washed in 1 × Tris buffer. TUNEL assay was then performed according to the manufacturer’s instructions.
Statistical analysis
Data were presented as mean ± SD for thoursee separate experiments. Comparions between groups were made with unpaired Student’s two-tailed t test and P < 0.05 was considered statistically significant.
Discussion
Acute myeloid leukemia is most often diagnosed in older people and children; more than 50 % of patients with AML are over-60 and 15-20 % are under 16 years old [
33,
34]. Chemotherapy is the only treatment option for the majority of AML patients and the most frequently used drugs are the deoxycytidine analog cytarabine and an anthoursacycline antibiotic, such as daunorubicin, idarubicin and the anthoursacenedione mitoxantrone [
3]. However, multiple chemotherapy treatments are intolerable for children and older people with AML, therefore, new effective therapies with fewer side effects are urgently needed. In this study, we demonstrated that ATRA had a synergistic cytotoxicity with TPT for AML
in vitro and
in vivo closely related to DNA damage-induced apoptosis via RARa activity inhibition.
ATRA used in combination with chemotherapy has been shown to improve the outcome of patients with breast cancer, lung cancer, ovarian cancer and gastric cancer, and only presents a few side effects, which suggests a potential for clinical application in AML [
35,
36]. Previous studies in ovarian, gastric and melanoma cancer cells have shown that retinoic acid has synergistic effects on DNA damage with the drug cisplatin [
37]. TPT is effective alone with cytotoxicity effects less than the doxorubicin (a classical AML drug) group (Additional file
1: Figure S1) or when combined with other drugs for AML, such as lapatinib, paclitaxel. However, TPT is limited by its toxicity [
14,
16,
17]. ATRA was proposed as a potential drug to enhance the anticancer activity of TPT. We demonstrated that ATRA decreases the concentration that causes DNA damage from 200 nM to 40 nM TPT.
DNA integrity is critical for proper cellular function and proliferation in AML. Once a DNA lesion occurs, it leads to replication-associated DNA double-strand breaks (DSBs) that eventually cause apoptosis if the damaged DNA cannot be properly repaired [
38]. Targeted therapies designed to induce apoptosis in leukemic cells are currently the most promising antileukemia strategies. We used flow cytometry analysis with PI staining, morphological evidence of apoptotic bodies, and immunoblotting to determine if the ratio of growth inhibition was induced by caspase-mediated apoptosis. The comet assay revealed that treatment with TPT and ATRA for one hour induces DNA SSBs in HL60 cells at high concentrations of TPT, although neither 40 nM TPT or 1 μM ATRA caused the SSBs first when using ATRA combined with TPT for one hour. Moreover, the DNA damage pathway and its transducers (Chk1, Chk2) were activated by TPT and ATRA at higher rates than TPT. Over time, the SSBs became DSBs and finally led to cell death by apoptosis.
ATRA binds to the retinoic acid receptor (RAR), RAR-alpha, RAR-beta, and RAR-gamma, which is bound to DNA as a heterodimer with the retinoid X receptor (RXR) in regions called retinoic acid response elements (RAREs), from there it affects gene transcription and modulates a wide variety of biological processes, such as apoptosis [
31]. In our study, RARα was knocked-down and the cells were susceptible to TPT, which increased the apoptosis rate. Therefore, we concluded that the existence of RARα was unfavorable for programmed cell death. The combination regime showed that ATRA downregulates the protein level of RARα, and this might be the key for synergistic effects in this anticancer therapy. As a result, DNA damage can be induced more easily with ATRA. However, the influence of RARα on TPT-induced DNA damage has not been explained, and the role of ATRA in the DNA damage pathway needs further exploration.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PHL, QJH and BY participated in the conception and design of the study. LL, ZFX, XMP, MC, GQL and HY acquire and analysis the data, PHL, JJS and LL constructed the manuscript. ZFX and XMP revise the manuscript critically. All authors read and approval the final manuscript.